The aim of this study is to compare the efficacy of calcium gluconate infusion versus cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who are at high risk for OHSS.
Ovarian hyperstimulation syndrome (OHSS) is a serious complication of assisted reproduction. Previous studies revealed that calcium gluconate infusion reduced the risk of OHSS. Other studies revealed that cabergoline (potent dopamine receptor agonist on D2 receptors)was effective in preventing OHSS. The aim of this study is to compare the efficacy of calcium gluconate infusion versus cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who are at high risk for OHSS.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
170
Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
Aljazeera hospital
Giza, Egypt
Riyadh Fertility and Reproductive Health center
Giza, Egypt
Moderate or severe ovarian hyperstimulation syndrome
Time frame: Within 4 weeks of HCG adminstration
The Number of Participants Who Achieved Ongoing Pregnancy
Time frame: 18 weeks after embryo transfer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.